Arcutis Biotherapeutics, Inc. · NASDAQ:ARQT
Arcutis Biotherapeutics — Q1 2025 Earnings Presentation
22 slides from Arcutis Biotherapeutics's earnings presentation, May 6, 2025
Slide 1: 1st Quarter 2025 Financial Results & Business Update
1st Quarter 2025 Financial Results & Business Update May 6, 2025
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation and the accompanying oral presentation those markets; our commercialization, marketing and the accompanying oral presentation are made pursuant to the contain forward-looking statements within the meaning of manufacturing capabilities and strategy; current and fut
Slide 3: Today's Speakers
Today’s Speakers Frank Watanabe Todd Edwards President & CEO Chief Commercial Officer Patrick Burnett, MD, PhD, FAAD Latha Vairavan Chief Medical Officer Chief Financial Officer ©Copyright 2025. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 3
Slide 4: Speakers & Agenda: Business Review
Speakers & Agenda Business Review Frank Watanabe President & CEO ©Copyright 2025. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. 4
Slide 5: Arcutis: Q1 2025 Key Takeaways
Arcutis: Q1 2025 Key Takeaways Strong Commercial Execution Steroid Conversion Advancement Robust Pipeline and IP • Q1 2025 net product revenue • # 1 prescribed topical for three • Anticipated approval of of $63.8 million for ZORYVE® major inflammatory skin ZORYVE foam 0.3% for scalp & (roflumilast)
Slide 6: Progress from Patient Opportunity to Rx Growth
Progress from Patient Opportunity to Rx Growth Total U.S. ZORYVE Addressable Market – 17M Patients ~24M Prescriptions1 6% 7% 17% 1% 69% Steroids Vit D analogs + Fixed Dose Combination Antifungal** TCI Branded Non-Steroidal Topicals * If approved Figures may not tie due to rounding ; PCP = primary ca
Slide 7: Speakers & Agenda: Commercial Update
Speakers & Agenda Commercial Update Todd Edwards Chief Commercial Officer ©Copyright 2025. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 7
Slide 8: Strong Net Product Revenues in Q1
Strong Net Product Revenues in Q1 Net Product Revenues $M • Q1 ‘25 net product revenues of $63.8M, +196% vs. prior year $65.3* $63.8 • Strong quarter over quarter volume growth continues $44.8 • GTN in the 50s, with typical Q1 GTN erosion due to annual $30.9 deductible and insurance resets • Expect
Slide 9: Steady TRx Growth for ZORYVE Portfolio
Steady TRx Growth for ZORYVE Portfolio – Reaching ~17,250 Weekly TRx (Rolling 4-Week Basis) 17,000 Cream 0.15% (AD) 15,000 R4 WEEK WEEKLY TRX Launch 13,000 TRx Growth Foam Launch 11,000 vs. Q4’24 vs. Q1 ‘24 9,000 Q1’25 7,000 +10% +169% 5,000 3,000 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan
Slide 10: Robust Rx Payor Reimbursement Delivering Profitable Scripts
Robust Rx Payor Reimbursement Delivering Profitable Scripts Versatile Portfolio ZORYVE Reaching Exceptional Overall Covered Prescriptions 3 National PBMs ZORYVE Cream 0.3% Covering ZORYVE Foam 0.3% ZORYVE ~80%+ Portfolio ZORYVE Cream 0.15% Prescriptions Covered by Insurance Profitable Script Pull Th
Slide 11: Tailoring to PCP Practice Dynamic & Selling Cycle
Tailoring to PCP Practice Dynamic & Selling Cycle Built Messaging Geared to PCPs Established National Pharmacy Strategy Conducive to PCPs Driving Frequency for Awareness, Trial & Usage in PCPs Positive Signals from Early Adopters ©Copyright 2025. Arcutis Biotherapeutics, Inc. — Presentation designed
Slide 12: Branded Topical Segment Grows as ZORYVE TRx Share Expands
Branded Topical Segment Grows as ZORYVE TRx Share Expands ZORYVE TRx Share Continues to Grow in the Branded Branded Topical Segment Grew by 50% Topical Segment R-4 Week TRx Share TCS Branded Non-Steroidal Topicals Zoryve TRx Share OPZELURA TRx Share VTAMA TRx Share EUCRISA TRx Share 100% 96% 94% 11%
Slide 13: ZORYVE is Unique in Dermatology, With Multiple Formulations & Indications
ZORYVE is Unique in Dermatology, With Multiple Formulations & Indications Plaque Psoriasis* Seborrheic Dermatitis Atopic Dermatitis 9M Patients 10M Patients 26M Patients ZORYVE 0.3% ZORYVE 0.15% Cream Foam* Cream Rapid, Reliable Relief Anywhere Rapid Itch Relief Once-daily steroid-free topical Safet
Slide 14: As HCPs Continue to Adopt the ZORYVE Portfolio Their Prescriptions Increase Substantially
As HCPs Continue to Adopt the ZORYVE Portfolio Their Prescriptions Increase Substantially 4 3 Sustained 2 Volume Growth Throughout 1 Four Indication Writers 2025 Three Indication Writers 31 TRx/HCP Two per R13 weeks Indication Writers One 11 TRx/HCP Indication Writer per R13 weeks 3 TRx/HCP per R13
Slide 15: Speakers & Agenda: R&D Update
Speakers & Agenda R&D Update Patrick Burnett, MD, PhD, FAAD Chief Medical Officer ©Copyright 2025. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 15
Slide 16: Continued Success With Clinical and Regulatory Milestones
Continued Success With Clinical and Regulatory Milestones Key Accomplishments / Milestones Indication Timing FDA Approval of ZORYVE Cream 0.3% Down to the Age of 6 Plaque PsO Seborrheic FDA Approval of ZORYVE Foam Down to the Age of 9 Dermatitis Positive INTEGUMENT-PED Topline in Ages 2-5 Atopic Der
Slide 17: Growing Consensus on Need for Shift From Steroids
Growing Consensus on Need for Shift From Steroids Risks of Topical Corticosteroid Therapy and Role for Beyond Skin Deep: The Systemic Advanced Targeted Topical Treatments for Inflammatory Impact of Topical Corticosteroids in Skin Diseases: an Expert Consensus Panel Dermatology “TCS and systemic cort
Slide 18: Improvement in Patients With Psoriasis Treated With ZORYVE Foam 0.3%
Improvement in Patients With Psoriasis Treated With ZORYVE Foam 0.3% 56-year-old female; White S-IGA: 3 S-IGA: 1 S-IGA:0 59-year-old female, White B-IGA: 3 B-IGA: 3 B-IGA: 0 BASELINE WEEK 2 WEEK 8 ©Copyright 2025. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. Indivi
Slide 19: Speakers & Agenda: Financial Results
Speakers & Agenda Latha Vairavan Financial Results Chief Financial Officer ©Copyright 2025. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. 19
Slide 20: Q1 2025 Financial Results
Q1 2025 Financial Results GAAP Reported $ Millions, Except Net Loss Per Share Q1 2025 Q1 2024 YoY Change Q4 2024 QoQ Change Product Revenues, Net $63.8 21.6 42.3 $69.4* (5.5) Other Revenues 2.0 28.0 (26.0) 2.0 0.0 Total Revenues $65.8 49.6 16.3 $71.4 (5.5) Cost of Sales 8.8 3.3 5.6 6.9 1.9 R&D Expen
Slide 21: Strong Cash Position In 2025
Strong Cash Position In 2025 $ Millions, except average shares GAAP Reported Cash Flow & Balance Sheet Data Q1 2025 Cash, cash equivalents, and marketable securities (Mar. 31, 2025) $198.7 Net cash used in operating activities 30.4 Total debt, net (Mar. 31, 2025) 107.6 Weighted average shares outsta
Slide 22: Thank You Q&A
Thank You Frank Watanabe Todd Edwards President & CEO Chief Commercial Officer Patrick Burnett, MD, PhD, FAAD Latha Vairavan Chief Financial Q&A Chief Medical Officer Officer ©Copyright 2025. Arcutis Biotherapeutics, Inc. All rights reserved. Presentation designed for an investor audience. 22
Arcutis Biotherapeutics — Q1 2025 Earnings Presentation on 6ix